The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China

Climacteric

Volumn 16, Issue 6, 2013, Pages 673-681

  Wen, Y ^a   Huang, H ^a   Wu, M ^a   Shen, K ^a   Pan, L ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Epithelial Ovarian Cancer; Hormone Replacement Therapy; Prognosis; Survival

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL VALERATE; TIBOLONE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SAFETY; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHINA; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; HORMONE REPLACEMENT THERAPY; HUMANS; KAPLAN-MEIER ESTIMATE; MENOPAUSE, PREMATURE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NORPREGNENES; OVARIAN NEOPLASMS; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84887975110     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2013.806472     Document Type: Article

References (29)

1. MacLennan AH. HRT in diffi cult circumstances: Are there any absolute contraindications? Climacteric 2011;14:409-17
2. Elit L, Esplen MJ, Butler K, Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 2001;1:149-56
3. Madalinska JB, Hollenstein J, Bleiker E, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005;23:6890-8
4. Gallicchio L, Whiteman MK, Tomic D, Miller KP, Langenberg P, Flaws JA. Type of menopause, patterns of hormone therapy use, and hot fl ashes. Fertil Steril 2006;85:1432-40
5. Salehi F, Dunfi eld L, Phillips K P, Krewski D, Vanderhyden B C. Risk factors for ovarian cancer: An overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 2008;11:301-21
6. Plaxe SC, Braly PS, Freddo JL, McClay E, Kirmani S, Howell SB. Profi les of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol 1993;81:651-4
7. Rodriguez M, Nguyen H N, Averette H E, et al. National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer 1994 ;73:1245-50
8. Duska LR, Chang YC, Flynn CE, et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer 1999;85:2623-9
9. Pouilles JM, Tremollieres F, Bonneu M, Ribot C. Infl uence of early age at menopause on vertebral bone mass. J Bone Miner Res 1994;9:311-15
10. V oort DJ, Weijer PH, Barentsen R. Early menopause: Increased fracture risk at older age. Osteoporos Int 2003;14:525-30
11. Farquhar D. Postmenopausal hormone replacement therapy for chronic disease prevention: Results from the Women's Health Initiative trial. CMAJ 2002;167:377-8
12. Wren B. Hormonal therapy and genital tract cancer. Curr Opin Obstet Gynecol 1996;8:38-41
13. Richardson GS. Endometrial cancer as an estrogen-progesterone target. N Engl J Med 1972;286:645-7
14. Weiss N S, Szekely D R, English D R, Schweid A I. E ndometrial cancer in relation to patterns of menopausal estrogen use. JAMA 1979;242:261-4
15. Fasching P A, Ekici A B, Adamietz B, et a l. B reast cancer risk-genes, environment, and clinical practice. Geburtsh Frauenheilk 2011;71:1056-66
16. Kummel S, Kolberg H C, Luftner D, et a l. B reast cancer 2011-new aspects. Geburtsh Frauenheilk 2011;71:939-53
17. Hein A, Thiel FC, Bayer CM, et al. Hormone replacement therapy and prognosis in ovarian cancer patients. Eur J Cancer Prev 2012;22:52-8
18. Biliatis I, Thomakos N, Rodolakis A, et al. Safety of hormone replacement therapy in gynaecological cancer survivors. J Obstet Gynaecol 2012;32:321-5
19. Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: The effect on survival. Menopause 2001;8:70-5
20. Bendel RB, Afi fi AA. Comparison of stopping rules in forward regression. J Am Stat Assoc 1977;72:46-53
21. P arker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-Term health outcomes in the NursesHealth Study. Obstet Gynecol 2009;113:1027-37
22. Shuster L T, Rhodes D J, Gostout B S, et a l. P remature menopause or early menopause: Long term health consequences. Maturitas 2010;65:161-6
23. Teede H J, Vincent A. H ormone therapy-where are we now? Aust Fam Physician 2011;40:280-5
24. Beral V;Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369:1703-10
25. Coughlin S S, Giustozzi A, Smith S J, Lee N C. A meta-Analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53:367-75
26. Eeles RA, Tan S, Wiltshaw E, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302:259-62
27. Ho S M. E strogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003;1:73
28. Guidozzi F, Daponte A. E strogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999;86:1013-18
29. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-Analysis. Obstet Gynecol 1998;92:472-9